Cargando…

A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays

INTRODUCTION: Commercially available serological assays for SARS-CoV-2 detect antibodies to either the nucleocapsid or spike protein. Here we compare the performance of the Beckman-Coulter SARS-CoV-2 spike IgG assay to that of the Abbott SARS-CoV-2 nucleocapsid IgG and Roche Anti-SARS-CoV-2 nucleoca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poore, Brad, Nerenz, Robert D., Brodis, Dina, Brown, Charles I., Cervinski, Mark A., Hubbard, Jacqueline A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Canadian Society of Clinical Chemists. Published by Elsevier Inc. 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188801/ https://www.ncbi.nlm.nih.gov/pubmed/34118242 http://dx.doi.org/10.1016/j.clinbiochem.2021.05.011

Ejemplares similares

Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance
por: Nerenz, Robert D., et al.
Publicado: (2021)

Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance
por: Nerenz, Robert D., et al.
Publicado: (2022)

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
por: Weidner, Lisa, et al.
Publicado: (2020)

Clinical Laboratory Utility of a Humanized Antibody in Commercially Available Enzyme Immunoassays for Coccidioidomycosis
por: Grill, Francisca J., et al.
Publicado: (2022)

Evaluation of 5 Commercially Available Zika Virus Immunoassays
por: Safronetz, David, et al.
Publicado: (2017)

Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
por: Resman Rus, Katarina, et al.
Publicado: (2021)

Comparative research on nucleocapsid and spike glycoprotein as the rapid immunodetection targets of COVID-19 and establishment of immunoassay strips
por: Liu, Dan, et al.
Publicado: (2021)

Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain
por: Poljak, Mario, et al.
Publicado: (2021)

Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
por: Santano, Rebeca, et al.
Publicado: (2021)

Validation of a Commercially Available Indirect Elisa Using a Nucleocapside Recombinant Protein for Detection of Schmallenberg Virus Antibodies
por: Bréard, Emmanuel, et al.
Publicado: (2013)

Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies
por: Nakagama, Yu, et al.
Publicado: (2022)

Evaluation of three commercially-available chikungunya virus immunoglobulin G immunoassays
por: De Salazar, Pablo M, et al.
Publicado: (2017)

Antibody detection of SARS-CoV spike and nucleocapsid protein
por: Chang, Mau-Sun, et al.
Publicado: (2004)

Thermodynamic effects of commercially available ice boots
por: Quintanar, Madison N., et al.
Publicado: (2018)

Validation of a commercially available SARS-CoV-2 serological immunoassay
por: Meyer, B., et al.
Publicado: (2020)

A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses
por: Lehmann, Christian, et al.
Publicado: (2008)

Human post‐infection serological response to the spike and nucleocapsid proteins of SARS‐CoV‐2
por: Xiao, Cheng, et al.
Publicado: (2020)

Diagnostic accuracy comparison of three fully automated chemiluminescent immunoassay platforms for the detection of SARS-CoV-2 antibodies
por: Parai, Debaprasad, et al.
Publicado: (2021)

Clinical evaluation of commercial automated SARS-CoV-2 immunoassays
por: Kittel, Maximilian, et al.
Publicado: (2021)

Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen
por: Dobaño, Carlota, et al.
Publicado: (2022)

Validation of dried blood spot sample modifications to two commercially available COVID-19 IgG antibody immunoassays
por: Zava, Theodore T, et al.
Publicado: (2020)

Publisher Correction: Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
por: Santano, Rebeca, et al.
Publicado: (2021)

Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19
por: Flinck, Heini, et al.
Publicado: (2021)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Do fully automated immunoassays for the evaluation of the immune response to SARS-CoV-2 are commutable?
por: Mairesse, A., et al.
Publicado: (2021)

Evaluation of commercially available point-of-care ultrasound for automated optic nerve sheath measurement
por: Moore, Brad T., et al.
Publicado: (2023)

Diagnostic Accuracy of Commercially Available Automated External Defibrillators
por: Nishiyama, Takahiko, et al.
Publicado: (2015)

Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use
por: Prince, Harry E., et al.
Publicado: (2020)

Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs
por: Van Elslande, Jan, et al.
Publicado: (2020)

Diagnostic performance of an automated chemiluminescence immunoassay for SARS-CoV-2 IgG and IgM antibodies detection: A real life experience
por: Villalta, Danilo, et al.
Publicado: (2021)

Detection of SARS-CoV-2 Nucleocapsid, Spike, and Neutralizing Antibodies in Vaccinated Japanese
por: Midorikawa, Rie, et al.
Publicado: (2022)

Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels
por: Tenjarla, Srini
Publicado: (2015)

Development of a Fully Automated Desktop Analyzer and Ultrahigh Sensitivity Digital Immunoassay for SARS-CoV-2 Nucleocapsid Antigen Detection
por: Chiba, Ryotaro, et al.
Publicado: (2022)

Assessment of commercial SARS-CoV-2 antibody assays, Jamaica
por: Butterfield, Tiffany R., et al.
Publicado: (2021)

Automated separation for heterogeneous immunoassays
por: Truchaud, A., et al.
Publicado: (1991)

Development of a recombinant truncated nucleocapsid protein based immunoassay for detection of antibodies against human coronavirus OC43()
por: Blanchard, Elisabeth G., et al.
Publicado: (2011)

Development of a Method for Detection of SARS-CoV-2 Nucleocapsid Antibodies on Dried Blood Spot by DELFIA Immunoassay
por: Damiani, Verena, et al.
Publicado: (2023)

A New ELISA to Overcome the Pitfalls in Quantification of Recombinant Human Monoclonal Anti-HBs, GC1102, by Commercial Immunoassays
por: Shin, Yong Won, et al.
Publicado: (2018)

Serum Level of Anti-Nucleocapsid, but Not Anti-Spike Antibody, Is Associated with Improvement of Long COVID Symptoms
por: Varnai, Reka, et al.
Publicado: (2022)

Serological Detection of SARS-CoV-2 IgG Using Commercially Available Enzyme Immunoassays on Dried Blood Spots Collected from Patients
por: Walker, Gregory J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2rmv9ghfkejlpm8of74712nt3q